{"id":30167,"date":"2024-12-08T10:47:08","date_gmt":"2024-12-08T00:47:08","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=30167"},"modified":"2025-01-09T07:47:01","modified_gmt":"2025-01-08T21:47:01","slug":"miles-prince-qa-update","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/","title":{"rendered":"Miles Prince Q&amp;A Update"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gmeae4d56 gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gm1de44b1\" class=\"wp-block-gutentor-m4 section-gm1de44b1 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm36b474\" class=\"wp-block-gutentor-m4-col col-gm36b474 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm36b474\" class=\"section-gm36b474 gutentor-col-wrap\">\n<h2 class=\"wp-block-heading has-text-align-center has-white-color has-text-color\" style=\"font-size:33px\">Prescient Therapeutics: Q&amp;A Update with Professor H. Miles Prince<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gmad0cc9c\" class=\"wp-block-gutentor-m4 section-gmad0cc9c gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm4ad4cf\" class=\"wp-block-gutentor-m4-col col-gm4ad4cf gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gm4ad4cf\" class=\"section-gm4ad4cf gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png\" alt=\"\" class=\"wp-image-30168\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/1030943340?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/playvideo-3-1.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm9a9d5f\" class=\"wp-block-gutentor-m4-col col-gm9a9d5f gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm9a9d5f\" class=\"section-gm9a9d5f gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">Reach Markets recently interviewed Professor H. Miles Prince AM &#8211; the Principal Investigator of our PTX-100 program &#8211; regarding its phase 1b trial and the encouraging outcomes it is delivering for patients.<a href=\"https:\/\/cwhlz04.na1.hubspotlinks.com\/Ctc\/LY+113\/cWHlz04\/VVBv5T1m0d4TW1XRfw_3VQ1mxW4FBnYy5plFKhN7swVx23qn9gW8wLKSR6lZ3mnW96PLm75vg61GW7hpcv91WrpYrW5mmq9p6PyB19Vlyd0s6Rdyy8W3mVGVt5jrN49W3NPjPQ5h4fbxW4DLpyD1c5zBZW2j1Pd-6KBgYrW1yq9GS2Z9JTLVV5FpK1JsB98W3mQ8sN2cfhPqVCpFMj26PrkLN2C1dwRH66WYW4FwDtB6VJX01W3FfvPd3_T7s0W7Cwpbb5PNjDVMYZClTnX1VVW4kWpfc1yBpQnN8h5c4_RYg5_W9jrk686tgGH2W5nPKkX51DJLzW3rDzZb8QPk1MW2qH9p22L8R2gW4BW0Bq7RM7-pW6LB1T87TBQQkW85hPpm1hGh2MVfX9qL3g80n4W5sPPSV5pRxkzdcxz4C04\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">In the video, Professor Prince discusses how:<\/p>\n\n\n\n<ul class=\"wp-block-list white\">\n<li>PTX100 targets an elusive pathway in treating T-cell lymphomas, offering hope for conditions like cutaneous T-cell lymphoma with limited options.<\/li>\n\n\n\n<li>The phase 1 study showed a [near] 50% response rate with prolonged remissions lasting beyond six months and, in some cases, several years.<\/li>\n\n\n\n<li>The drug is really safe, and there is optimism about its potential for expedited regulatory approval given the unmet clinical need.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 8 December 2024 at 12:00pm (AEDT)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gm26e4750 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"wp-block-heading speak has-text-color\" style=\"color:#ffcc00\">Featured Speaker<\/h4>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n\n\n\n<section id=\"gmf7711a6\" class=\"wp-block-gutentor-m4 section-gmf7711a6 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmf7ecbb\" class=\"wp-block-gutentor-m4-col col-gmf7ecbb gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gmf7ecbb\" class=\"section-gmf7ecbb gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gm58370d\" class=\"wp-block-gutentor-m4-col col-gm58370d gutentor-single-column  grid-lg-6 grid-md-12 grid-12\"><div id=\"section-gm58370d\" class=\"section-gm58370d gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"400\" height=\"400\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-Profile-Photo-1.jpg\" alt=\"\" class=\"wp-image-30170\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-Profile-Photo-1.jpg 400w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-Profile-Photo-1-300x300.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-Profile-Photo-1-150x150.jpg 150w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\">Professor H. Miles Prince<\/h3>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center speaker-title has-white-color has-text-color\">Hematologist and Professor of Medicine<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Professor H. Miles Prince is an internationally recognised Australian hematologist and a Professor at both Melbourne and Monash Universities. He is also the Professor\/Director of Molecular Oncology and Cancer Immunology at the Epworth Centre, and a Hematologist at the Peter MacCallum Cancer Centre. As a global expert in T-cell lymphomas, Professor Miles acts as the Principal Investigator for the PTX-100 clinical trials. He holds major Australian, American and European research grants and has published over 450 journal articles. In 2014 he was awarded a Member of the Order of Australia (general division) for significant services to blood cancer research, patient care and philanthropy leadership.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm499176\" class=\"wp-block-gutentor-m4-col col-gm499176 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm499176\" class=\"section-gm499176 gutentor-col-wrap\">\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":30168,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-30167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Miles Prince Q&amp;A Update - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Miles Prince Q&amp;A Update - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-08T00:47:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-08T21:47:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"enouvoteam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"enouvoteam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/\"},\"author\":{\"name\":\"enouvoteam\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"headline\":\"Miles Prince Q&amp;A Update\",\"datePublished\":\"2024-12-08T00:47:08+00:00\",\"dateModified\":\"2025-01-08T21:47:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/\"},\"wordCount\":253,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/\",\"name\":\"Miles Prince Q&amp;A Update - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png\",\"datePublished\":\"2024-12-08T00:47:08+00:00\",\"dateModified\":\"2025-01-08T21:47:01+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Miles Prince Q&amp;A Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\",\"name\":\"enouvoteam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"caption\":\"enouvoteam\"},\"sameAs\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\"],\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Miles Prince Q&amp;A Update - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Miles Prince Q&amp;A Update - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/","og_site_name":"PTX Therapeutics","article_published_time":"2024-12-08T00:47:08+00:00","article_modified_time":"2025-01-08T21:47:01+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png","type":"image\/png"}],"author":"enouvoteam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"enouvoteam","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/"},"author":{"name":"enouvoteam","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"headline":"Miles Prince Q&amp;A Update","datePublished":"2024-12-08T00:47:08+00:00","dateModified":"2025-01-08T21:47:01+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/"},"wordCount":253,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/","name":"Miles Prince Q&amp;A Update - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png","datePublished":"2024-12-08T00:47:08+00:00","dateModified":"2025-01-08T21:47:01+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Miles-Prince-QA-Update.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/miles-prince-qa-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Miles Prince Q&amp;A Update"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c","name":"enouvoteam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","caption":"enouvoteam"},"sameAs":["https:\/\/template.reachmarkets.com.au\/investorportal"],"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=30167"}],"version-history":[{"count":10,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30167\/revisions"}],"predecessor-version":[{"id":30528,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30167\/revisions\/30528"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/30168"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=30167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=30167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=30167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}